Related Experiment Videos
[Interactions between the human immunodeficiency virus and hepatitis C virus]
1Unité d'hépatologie, hôpital Necker, Paris, France.
Insights
Hepatitis C virus (HCV) infection affects 9% of human immunodeficiency virus (HIV)-infected individuals, worsening liver disease. Combined therapies show promise for treating HCV in HIV patients.
Area of Science:
- Virology
- Immunology
- Hepatology
Context:
- Hepatitis C virus (HCV) infection is prevalent in 9% of human immunodeficiency virus (HIV)-infected individuals.
- HIV infection exacerbates HCV replication, leading to more severe liver damage and faster cirrhosis progression.
- Understanding the interplay between HCV and HIV is crucial for managing coinfection.
Purpose:
- To evaluate the reciprocal interactions between HCV and HIV.
- To highlight the need for early diagnosis and treatment of HCV in HIV-infected patients.
- To assess the impact of combined therapies on HCV treatment outcomes.
Summary:
- HCV infection in HIV-positive individuals often results in chronic hepatitis and persistent viremia.
- HIV accelerates HCV replication, increasing the risk of severe liver lesions and cirrhosis.
- Current treatment options like interferon alpha have limited long-term efficacy, necessitating novel therapeutic strategies.
Impact:
- Combined therapies, particularly those including ribavirin, may improve long-term response rates.
- The influence of antiretroviral triple therapy and immune restoration on HCV natural history requires further investigation.
- Future research should focus on assessing how these advancements alter HCV infection outcomes in coinfected patients.
Introduction:
Prevalence of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected subjects is around 9%, varying according to the mode of contamination. Reciprocal interactions between the two viruses have to be evaluated.
Current Knowledge And Key Points:
HCV infection is usually associated with chronic hepatitis and detectable viremia in HIV-infected patients. HIV infection enhances HCV replication, leading to more severe liver lesions and to a more rapid occurrence of cirrhosis. This underlines the need for both early diagnosis and therapy in order to avoid severe evolution of the liver disease.
Future Prospects And Projects:
Even though the rate of long-term responses to interferon alpha is low, improvement may be expected from combined therapies, especially with combination including ribavirin. The impact of both antiretroviral triple therapy and accompanying immune restoration on natural history and treatment of HCV infection has to be assessed, as the above mentioned consensual conclusions may be modified in a near future.